Literature DB >> 16581249

Gankyrin: a new oncoprotein and regulator of pRb and p53.

Simon Dawson1, Hiroaki Higashitsuji, Anthony J Wilkinson, Jun Fujita, R John Mayer.   

Abstract

Gankyrin is a new oncoprotein with potent cell cycle and apoptotic properties that is overexpressed early in hepatocarcinogenesis and in hepatocellular carcinomas. Gankyrin regulates the phosphorylation of the retinoblastoma protein (pRb) by CDK4 and enhances the ubiquitylation of p53 by the RING ubiquitin ligase MDM2. Purified preparations of the 26S proteasome contain gankyrin, which specifically interacts with the S6b (Rpt3) ATPase of the 19S regulator. In conclusion, gankyrin is a small versatile cell cycle regulator that illustrates the essential interplay between the ubiquitin proteasome system and gene expression in the cell. Here, we discuss the activities of gankyrin and present a model for its function in the regulation of pRb and p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581249     DOI: 10.1016/j.tcb.2006.03.001

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  32 in total

Review 1.  Assembly, structure, and function of the 26S proteasome.

Authors:  Lynn Bedford; Simon Paine; Paul W Sheppard; R John Mayer; Jeroen Roelofs
Journal:  Trends Cell Biol       Date:  2010-04-26       Impact factor: 20.808

2.  Mechanical unfolding of an ankyrin repeat protein.

Authors:  David Serquera; Whasil Lee; Giovanni Settanni; Piotr E Marszalek; Emanuele Paci; Laura S Itzhaki
Journal:  Biophys J       Date:  2010-04-07       Impact factor: 4.033

Review 3.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

4.  Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells.

Authors:  Jiang-Hong Man; Bing Liang; Yue-Xi Gu; Tao Zhou; Ai-Ling Li; Tao Li; Bao-Feng Jin; Bing Bai; Hai-Ying Zhang; Wei-Na Zhang; Wei-Hua Li; Wei-Li Gong; Hui-Yan Li; Xue-Min Zhang
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

Review 5.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

6.  Contributions of conserved TPLH tetrapeptides to the conformational stability of ankyrin repeat proteins.

Authors:  Yi Guo; Chunhua Yuan; Feng Tian; Kun Huang; Christopher M Weghorst; Ming-Daw Tsai; Junan Li
Journal:  J Mol Biol       Date:  2010-04-14       Impact factor: 5.469

Review 7.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

Review 8.  Scratching the Surface: Resurfacing Proteins to Endow New Properties and Function.

Authors:  Alex M Chapman; Brian R McNaughton
Journal:  Cell Chem Biol       Date:  2016-05-19       Impact factor: 8.116

9.  Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.

Authors:  Anjali Mahajan; Yi Guo; Chunhua Yuan; Christopher M Weghorst; Ming-Daw Tsai; Junan Li
Journal:  J Mol Biol       Date:  2007-08-22       Impact factor: 5.469

10.  Chaperone-mediated pathway of proteasome regulatory particle assembly.

Authors:  Jeroen Roelofs; Soyeon Park; Wilhelm Haas; Geng Tian; Fiona E McAllister; Ying Huo; Byung-Hoon Lee; Fan Zhang; Yigong Shi; Steven P Gygi; Daniel Finley
Journal:  Nature       Date:  2009-06-11       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.